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ABSTRACT Bordetella pertussis causes pertussis, a respiratory disease that is most severe for infants. Vaccination was introduced
in the 1950s, and in recent years, a resurgence of disease was observed worldwide, with significant mortality in infants. Possible
causes for this include the switch fromwhole-cell vaccines (WCVs) to less effective acellular vaccines (ACVs), waning immunity,
and pathogen adaptation. Pathogen adaptation is suggested by antigenic divergence between vaccine strains and circulating
strains and by the emergence of strains with increased pertussis toxin production.We applied comparative genomics to a world-
wide collection of 343 B. pertussis strains isolated between 1920 and 2010. The global phylogeny showed two deep branches; the
largest of these contained 98% of all strains, and its expansion correlated temporally with the first descriptions of pertussis out-
breaks in Europe in the 16th century. We found little evidence of recent geographical clustering of the strains within this lineage,
suggesting rapid strain flow between countries. We observed that changes in genes encoding proteins implicated in protective
immunity that are included in ACVs occurred after the introduction ofWCVs but before the switch to ACVs. Furthermore, our
analyses consistently suggested that virulence-associated genes and genes coding for surface-exposed proteins were involved in
adaptation. However, many of the putative adaptive loci identified have a physiological role, and further studies of these loci may
reveal less obvious ways in which B. pertussis and the host interact. This work provides insight into ways in which pathogens
may adapt to vaccination and suggests ways to improve pertussis vaccines.
IMPORTANCE Whooping cough is mainly caused by Bordetella pertussis, and current vaccines are targeted against this organism.
Recently, there have been increasing outbreaks of whooping cough, even where vaccine coverage is high. Analysis of the genomes
of 343 B. pertussis isolates from around the world over the last 100 years suggests that the organism has emerged within the last
500 years, consistent with historical records. We show that global transmission of new strains is very rapid and that the world-
wide population of B. pertussis is evolving in response to vaccine introduction, potentially enabling vaccine escape.
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Bordetella pertussis is the primary causative agent of pertussis(whooping cough), a respiratory disease which is particularly
severe for unvaccinated infants. Indeed, pertussis was a major
cause of infant deaths before the introduction of vaccination. Even
today, pertussis is a significant cause of child mortality, and esti-
mates from theWHO suggest that, in 2008, about 16million cases
of pertussis occurredworldwide, 95%ofwhichwere in developing
countries, and that about 195,000 children died from this disease
(1).
There has beenmuch speculation about the origin of pertussis.
Although the disease has very characteristic symptoms and high
mortality in unvaccinated children, references to pertussislike
symptoms have not been found in the ancient European litera-
ture. The first documented pertussis epidemic occurred in Paris in
1578 (2). In the 16th and 17th centuries, descriptions of pertussis
epidemics in Europe were documented more frequently in the
literature, possibly suggesting an expansion of the disease (3). The
apparent emergence of pertussis in Europe over the last 600 years
may be due to import, as symptoms similar to pertussis were de-
scribed in a classical Korean medical textbook from the 15th cen-
tury (4).
The introduction of vaccination has significantly reduced the
pertussis burden; however, in the 1990s, a resurgence of pertussis
was observed in many highly vaccinated populations (5). The
years 2010 to 2012 have seen particularly large outbreaks in Aus-
tralia, the Netherlands, the United Kingdom, and the United
States, with significant mortality in infants (6–10). The possible
causes for the pertussis resurgence are still under debate and in-
clude waning vaccine-induced immunity, the switch from whole-
cell vaccines (WCVs) to less effective acellular vaccines (ACVs),
and pathogen adaptation (5, 11–13). The contributions of these
causes probably differ from country to country. The importance
of pathogen adaptation is suggested by the antigenic divergence of
circulating strains from vaccine strains and the emergence of
strains which produce more toxin (reviewed in reference 5). An-
tigenic divergence initially involved relatively few mutations, af-
fecting up to 12 amino acids in the five B. pertussis proteins in-
cluded in ACVs, i.e., filamentous hemagglutinin (FHA), pertactin
(Prn), the Ptx A subunit (PtxA), serotype 2 fimbriae (Fim2), and
serotype 3 fimbriae (Fim3). In the 1980s, strains emerged with a
novel allele for the Ptx promoter, designated ptxP3. Strains carry-
ing the ptxP3 allele have been shown to produce more Ptx in vitro
(14). Significantly,mutations in these six loci have been associated
with clonal sweeps (15). The emergence of the ptxP3 lineage is
particularly remarkable because ptxP3 strains have risen to pre-
dominance, replacing the resident ptxP1 strains in many Euro-
pean countries, the United States, and Australia (14, 16–21). Fur-
thermore, the emergence of ptxP3 strains is associated with
increases in pertussis notifications in at least two countries (14,
20). However, another study found that the resurgence of pertus-
sis in the United States was correlated with the fim3-2 allele and
not with ptxP3 (22). More recently, strains have emerged that do
not express one or more components of pertussis vaccines, in
particular, Prn and FHA (17, 23–25).
Together with at least 425 other genes, the genes for the five
B. pertussis proteins used in ACVs belong to the so-called Borde-
tella virulence gene (Bvg) regulon, consisting of a sensory trans-
duction system which translates environmental cues into changes
in gene expression (26, 27). Low temperatures and high sulfate
and nicotinic acid concentrations are signals known to suppress
genes in the Bvg regulon (28). As essentially all known virulence-
associated proteins require Bvg for their expression, Bvg activa-
tion is used to identify genes that play a role in the interactionwith
the host, even if the function of that gene is not known.
Key questions concerning pertussis are the origin of the dis-
ease, the forces that have driven the shifts in B. pertussis popula-
tions, and the role of these shifts in the resurgence of pertussis. To
address these questions, we have determined the global popula-
tion structure of B. pertussis by whole-genome sequencing of 343
strains from 19 countries isolated between 1920 and 2010. Phylo-
genetic analysis revealed a deep divergence between two lineages
of B. pertussis, possibly suggesting two independent introductions
of the organism from an unknown reservoir. Bayesian methods
showed that the date of the common ancestor of one of these
lineages correlates with the first descriptions of pertussis in Eu-
rope and that this lineage has increased in diversity subsequent to
the introduction of vaccination. Our analyses revealed that many
(putative) adaptivemutations occurred in the period in which the
WCV was used, suggesting that vaccination was the major force
driving changes in B. pertussis populations. Furthermore, we ex-
tend our previous observation that the mutation leading to the
ptxP3 allele occurred once and that the ptxP3 strains have spread
and diversified worldwide (29). Finally, we identified novel puta-
tive adaptive loci, the analysis of which may cast new light on the
persistence and resurgence of pertussis and point to ways to in-
crease the effectiveness of vaccination.
RESULTS AND DISCUSSION
Phylogeny and phylogeography of B. pertussis.We explored the
evolutionary relationships among 343B. pertussis strains collected
from 19 countries representing six continents. Strains were iso-
lated between 1920 and 2010 (Table 1; see Table S1 in the supple-
mental material). Illumina reads were aligned to the reference
genome B. pertussis Tohama I (30), and 5,414 single-nucleotide
polymorphisms (SNPs) were identified (Table S2), corresponding
to a mean SNP density of 0.0013 SNPs/bp and an estimated mu-
tation rate of 2.24 107 per site per year. We generated a max-
imum likelihood phylogeny representing the B. pertussis global
population structure (Fig. 1A; Fig. S1). This phylogeny revealed
two deep branches separated by 1,711 SNPs. Branch I contained
only a small number of strains (1.7%), which were isolated be-
tween 1954 and 2000 and harbor ptxA5 and ptxP4 alleles (coding
for the Ptx A subunit and the Ptx promoter, respectively), which
are infrequently isolated nowadays. This branch includes the type
strain 18323. Branch II contained strains isolated between 1920
and 2010 which fall into the more common ptxA2 ptxP1, ptxA1
ptxP1, and ptxA1 ptxP3 types (Fig. 1B). Bayesian phylogenetic
analysis estimated that these two lineages diverged around
2,000 years ago (median, 2,296 years; 95% confidence interval
[CI], 1,428 to 3,340), which may reflect the loss of intermediate
lineages over time or may represent two independent introduc-
tions of B. pertussis into the global human population from an
unknown reservoir. The adaptation of B. pertussis to the human
population has been postulated to have involved a significant evo-
lutionary bottleneck and was associated with considerable gene
loss and gene inactivation due to insertion sequence (IS) element
expansion and mutations (30), a process commonly seen in host-
restricted bacteria (31). In the analysis of the Tohama I genome
sequence, it was estimated that up to 25% of genes were lost rela-
tive to those present in the common ancestorwithBordetella para-
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pertussis (30), and 9.5% of those remaining were inactivated and
were only present as pseudogenes. A manual comparison of 50%
of the pseudogenes in Tohama I and strain 18323 (representing
the two deep branches) showed that 72% of the pseudogenes were
shared, and of those, all had identical inactivating mutations (Ta-
ble S3). This indicates that the host restriction of B. pertussis and
the associated bottleneck occurred before the divergence of these
two lineages and long before the first description of the disease.
The most parsimonious explanation would suggest that this pro-
cess involved adaptation to the human host, and this would indi-
cate that pertussis was introduced into the global population twice
from a reservoir in an unsampled human population or that the
intermediate diversity has been lost. The alternative explanation,
that the adaption was to another host, would require both an
unknown reservoir species and two separate introductions into
the human population.
Three vaccine strains were included in this study, Tohama I
and twoAmerican strains (strains B308 and B310) (see Table S1 in
the supplemental material), which were placed in branch II. The
vaccine strains and the reference genome, Tohama I, both repre-
sent lineages and antigenic genotypes for which recent isolations
are rare. Most recent B. pertussis isolates stem from a lineage (lin-
eage IIb) within branch II, which appeared before the introduc-
tion of vaccination but has expanded since. A Bayesian phyloge-
netic and skyline analysis of isolates from lineage IIb for which
isolation date information was available (Fig. 1B; Fig. S2) reveals
that there was no evidence of loss of diversity (represented by the
effective population size) after the introduction of vaccination.
This was unexpected, as one would assume that the introduction
of vaccination would lead to a decrease in population diversity, as
the selective pressure may lead to a population bottleneck
whereby only those lineages that escape the vaccine may survive.
Indeed, some previous studies have observed such a decrease in
population diversity following the introduction of vaccination.
However, these studies were based on geographically more re-
stricted pathogen populations (32–34). Our results suggest that,
despite whole-cell vaccines reducing the prevalence ofmany of the
older lineages, they have not been eradicated completely, so the
diversity of these lineages is still present in the B. pertussis popu-
lation. The explanation for this may be that such lineages have
persisted in geographical regions where vaccination has not be-
come routine. In fact, there is some evidence from the skyline
analysis that population diversity increased in lineage IIb after
vaccine introduction. Although the effect of sampling density be-
fore and after vaccine introduction is unclear, the shape of the
phylogenetic tree suggests that this increase was primarily the re-
sult of the expansion of the ptxA1 lineage, which may represent
some level of vaccine escape in countries where vaccination had
been introduced.
A second increase in effective population size (diversity) coin-
cides with the emergence and expansion of a lineage carrying the
ptxP3 allele. In themid-1990s, there appears to be a drop in diver-
sity, correlating with the loss of a number of early ptxA1 lineages,
and perhaps corresponding with the introduction of the ACV in
the mid-1990s. However, diversity very quickly increased again
with the expansion of a sublineage of the ptxP3 group that ac-
quired a fim3-2 allele, again suggesting the selection and diversifi-
cation of vaccine escape lineages.
There is little evidence of geographical structure in the phylo-
genetic tree (Fig. 1B). The sampling of the older branch I lineages
is sparse in space and time, making inference difficult. However,
the ptxA1 lineage is clearly dispersed globally, and the ptxP3 and
fim3-2 lineages show no geographical clustering at all, indicating
that there has been very rapid global spread of these recently
evolved lineages.
Temporal trends in frequencies of alleles coding for vaccine
components. To explore the influence of vaccination on the
B. pertussis population, we focused on genes coding for antigens
known to induce protection and included in modern ACVs, in-
cluding serotype 2 fimbriae (fim2), serotype 3 fimbriae (fim3),
pertactin (prn), and the A subunit of Ptx (ptxA) (5, 35). Although
it is used inACVs, filamentous hemagglutininwas not included, as
accurate assembly and assignment of SNPswas not possible due to
the presence of repeats and paralogs. As previous studies suggest
that variation in the Ptx promoter, ptxP, was linked to clonal
sweeps (15, 21, 33), we also included ptxP alleles in our analyses.
TABLE 1 Geographic origin and period of isolation of B. pertussis strains used in this study
Continent Country No. of strains Isolation period Introduction of vaccination
Africa Kenya 17 1975 1980s
Senegal 4 1990-1993 1980s
Asia China 2 1957 Early 1960s
Hong Kong 5 2002-2006 1950s
Japan 17 1988-2007 1950s
Taiwan 23 1992-2007 1954
Australia Australia 37 1974-2007 1953
Europe Denmark 9 1962-2007 1961
Finland 16 1953-2006 1952
France 11 1993-2007 1959
Italy 15 1994-1995 1995
Netherlands 60 1949-2010 1953
Poland 16 1963-2000 1960
Russia 2 2001-2002 1956-1959
Sweden 23 1956-2006 1953
United Kingdom 20 1920-2008 1957
North America Canada 17 1994-2005 1943
USA 36 1935-2005 1940s
South America Argentina 13 1969-2008 1970s
Total 343 1920-2010
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FIG 1 Global phylogeny of B. pertussis. (A) Outline of the maximum likelihood phylogeny of all B. pertussis samples sequenced, showing the deep divergence
between lineages I and II. The complete tree is shown in Fig. S1 in the supplemental material. (B) Bayesian phylogeny of samples for which date information was
available within the most common clade of B. pertussis. The position of a node along the x axis of the tree represents the median date reconstructed for that node
across all sampled trees. Dates of whole-cell vaccine (WCV) and acellular vaccine (ACV) periods are shown as background colors behind the tree. To the right
of the tree, the continent of origin of isolates is indicated by the first column of horizontal bars, colored according to the inset key. The remaining nine columns
represent loci within the ptx operon, the fim2 and fim3 loci, and the prn locus, with assigned numerical alleles colored according to the key. The positions of
reference strains 18323 and Tohama I (T) are indicated in panels A and B with green filled circles. Black filled circles represent the American vaccine strains B308
(A) and B310 (B) (Table S1). Red circles indicate the major changes in antigen gene alleles in proteins used in current ACVs (from ptxA2 to ptxA1, fim2-1 to
fim2-2, ptxP1 to ptxP3, and fim3-1 to fim3-2).
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With the exception of ptxA10, prn16, and prn17, all alleles have
been described before, and references and accession numbers are
given in Text S1 in the supplemental material. The major changes
in antigen gene alleles (from ptxA2 to ptxA1, fim2-1 to fim2-2,
ptxP1 to ptxP3, and fim3-1 to fim3-2) are marked on the nodes in
the phylogenetic tree in Fig. 1B. In most countries, vaccination
was introduced between 1940 and 1960 (Table 1), and worldwide,
many different B. pertussis strains have been used to produce vac-
cines. A compilation of 23 vaccine strains revealed that the most
prevalent alleles found in vaccine strains were fim2-1 (82%), fim3-
1 (100%), and prn1 (74%) or prn7 (22%) (Table S4). If oneDutch,
one Swedish, and one acellular vaccine strain were omitted, all
other vaccine strains carried the fim2-1, fim3-1, and prn1/7 alleles.
More diversity in vaccine strains was observed with respect to
ptxA, for which four alleles, ptxA1, ptxA2, ptxA3, and ptxA4, were
observed at frequencies of 13%, 52%, 4%, and 31%, respectively.
For twelve vaccine strains, the ptxP allele has been determined.
The ptxP1 allele and ptxP2 allele were found in 67% and 33%,
respectively. Most ACVs are derived from two strains, Tohama I
and 10536, which carry the alleles fim2-1, fim3-1, prn1, ptxA2, and
ptxP1 and fim2-1, fim3-1, prn7, ptxA4, and ptxP2, respectively.
To investigate temporal trends in allele frequencies, we defined
four periods to reflect the worldwide changes in pertussis vaccina-
tion (Fig. 2): the earlyWCVperiod (earlier than 1960; n 22), the
period in which mainly WCVs were used (WCV period, 1960 to
1995; n 126), the period in which both WCVs and ACVs were
used (WCV/ACV period, 1996 to 2000; n  75), and finally, a
period in which mainly ACVs were used (ACV period, later than
FIG 2 Temporal trends in strain frequencies for the fim2 (A), fim3 (B), ptxA (C), ptxP (D), and prn (E) alleles. Four periods were defined to reflect the worldwide
changes in pertussis vaccination, the earlyWCVperiod (earlier than 1960), the period in whichmainlyWCVswere used (WCVperiod, 1960 to 1995), the period
in which both WCVs and ACVs were used (WCV/ACV period, 1996 to 2000), and a period in which mainly ACVs were used (ACV period, later than 2000).
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2000; n 118).We presumed that the effect of vaccination on the
B. pertussis populationwas small in the earlyWCVperiod (15, 33).
Obviously, the relationship between the periods and the vaccina-
tion history can only be approximate.
Two fim2 alleles were observed in the worldwide collection of
strains, fim2-1 (the vaccine type) and fim2-2, the products of
which differed in a single amino acid. The fim2-1 allele predomi-
nated in all four periods (frequencies 77% to 98%), whereas the
fim2-2 allele was found at low frequencies (2% to 23%) in all four
periods (Fig. 2A). Phylogenetic analysis (Fig. 1B) indicated that
themutation leading to the fim2-2 allele arose twice within lineage
IIb but also occurred on the branch leading to lineage IIa. Bayesian
analysis suggested that, within lineage IIb, the mutation occurred
between 1970 and 1984 (95% CI, 1956 to 1992) on the first occa-
sion and between 1996 and 2002 (95% CI, 1995 to 2002) on the
second. Thus, the first mutation arose in theWCV period and the
most recent mutation occurred in the WCV/ACV period.
More variation was found in fim3, for which five alleles were
identified. As one allele contains a silent mutation, the five alleles
code for four distinct proteins: Fim3-1, Fim3-2, Fim3-3, and
Fim3-6. The fim3-1 (the vaccine type) and fim3-2 alleles were pre-
dominant (Fig. 2B). The polymorphic amino acid residue in fim3-
2 relative to the sequence of fim3-1 is located in a surface epitope
that has been shown to interact with human serum (36). The
fim3-1 allele has always predominated, but the fim3-2 allele, which
was first detected in theWCVperiod (frequency 1%), increased in
frequency to 37% in the ACV period. Our analyses agreed with
this observation, with the mutation resulting in the fim3-2 allele
predicted to have occurred between 1986 and 1989 (95%CI, 1982
to 1992).
Eight ptxA alleles were found worldwide, two of which con-
tained silent mutations. Thus, the eight alleles resulted in six pro-
tein variants (PtxA1, PtxA3, PtxA4, PtxA5, PtxA9, and PtxA10),
mostly differing by one or two amino acids. Three alleles were
predominant, ptxA1, ptxA2, and ptxA4 (respective frequencies,
78%, 18%, and 2%). The ptxA2 and ptxA4 alleles predominated in
the early WCV period (respective frequencies, 64% and 23%).
Our analyses show that the ptxA1 allele arose between 1921 and
1932 (95% CI, 1905 to 1942), before the introduction of vaccina-
tion. It increased in frequency from only 5% in the early WCV
period to 68%, 92%, and 90% in subsequent periods (Fig. 2C).
Althoughmost (46%) of the vaccine strains harbor ptxA2, 17%do
contain ptxA1.
Fourteen ptxP alleles were observed, of which ptxP1 and ptxP3
predominated (total frequencies of 60% and 32%, respectively).
Strains with ptxP1 were most common in the early WCV and
WCV periods (respective frequencies, 68% and 83%) but were
replaced by ptxP3 strains in the last two periods (the ptxP3 fre-
quencies in the WCV/ACV and ACV periods were 48% and 57%,
respectively) (Fig. 2D). Bayesian analysis suggested that the mu-
tation resulting in the ptxP3 allele arose between 1974 and 1977
(95% CI, 1970 to 1981), i.e., in the WCV period.
Twelve prn alleles were identified, of which 11 led to protein
variants (Prn1 to -7, Prn10 to -12, and Prn16). Prn-deficient
strains were not detected, presumably because these strains
reached significant frequencies in a later period than analyzed in
this study. Three alleles predominated in our worldwide collec-
tion, prn1 (42%), prn2 (38%), and prn3 (12%). In the early WCV
period, 67% of the strains harbored prn1 (the vaccine type), with
prn2 and prn3 alleles emerging in the WCV period. While the
frequency of the prn3 allele remained more or less constant (10%
to 17%), prn2 increased in frequency from 18% in the WCV pe-
riod to 65% in the ACV period (Fig. 2E). Variation in prn mainly
occurs by variation in numbers of repeats, a reversible process
which is relatively frequent compared to point mutations. There-
fore, many prn variants were homoplasic in our tree due to con-
vergent evolution.
In conclusion, based on these five genes, it appears that the
worldwide B. pertussis population has changed significantly in the
last 60 years, consistent with other studies using temporally and
geographically less diverse collections (15, 17–19, 21, 22, 32, 34,
37–40). Most changes resulted in genetic divergence from vaccine
strains, consistent with vaccine-driven immune selection. Indeed,
Bayesian analyses suggested that the non-vaccine-type alleles
ptxP3 and fim3-2 arose in the period in which the WCV was used
widely. Recently, strains have been identifiedwhich do not express
Prn and/or FHA (17, 23, 24), and the emergence of these strains
may be associated with the introduction of ACVs. In this and
previous work, the largest number of alleles were observed for
ptxP (n  14), prn (n  12), and ptxA (n  8). The number of
allelesmay be related to the degree of diversifying selection caused,
e.g., by the immune status of the host population or other (fre-
quent) changes in the ecology of B. pertussis.
Previous studies have shown that changes in fim3, ptxA, prn,
and ptxP are associated with selective sweeps (15, 19, 22, 32), im-
plying a significant effect on strain fitness. Furthermore, variation
in ptxA, ptxP, and prn has been shown to affect bacterial coloni-
zation of naive and vaccinated mice (40–45), underlining the bi-
ological significance of these changes. However, in one study, the
effects were not observed (46).
Identificationof additional loci potentially involved in adap-
tation. In addition to focusing on genes coding for vaccine com-
ponents, we used a more comprehensive approach to identify pu-
tative adaptive loci. To detect genes important for adaptation,
dN/dS ratios (ratio of nonsynonymous to synonymous substitu-
tion rates) are widely used. This method was originally developed
for the analysis of divergent species and needs a large number of
substitutions for a statistically reliable analysis (47–49). However,
B. pertussis strains are highly related and differ by less than 0.1% in
their genomic sequences. Recent studies have shown that the pri-
mary driver of dN/dS ratios in such closely related strains is time,
not selection (48). Furthermore, the approach using dN/dS ratios
assumes that silent mutations are neutral. However, silent muta-
tions in genes can significantly affect gene expression (50). Finally,
dN/dS ratios are not useful to detect diversifying selection in in-
tergenic regions. Therefore, we chose to assess diversifying selec-
tion by focusing on SNP densities and homoplasy.
SNPdensities.Weexploredwhether particular gene categories
had a significantly higher SNP density than the overall SNP den-
sity of the whole genome, 0.0013 SNPs/bp. The gene categories
used were defined by Parkhill et al. (30), with modifications, i.e.,
pseudogenes and genes known or assumed to be associated with
virulence were placed in separate categories. In all, 24 gene cate-
gories were defined (Fig. 3A; see Table S5 in the supplemental
material). As expected, gene categories involved in housekeeping
functions, which are generally conserved, showed the lowest SNP
densities (0.0007 to 0.00012 SNPs/bp). The four categories with
the highest SNP density were virulence associated (0.0016 SNPs/
bp), transport/binding (0.0015 SNPs/bp), protection responses
(0.0014 SNPs/bp), and pseudogenes (0.0014 SNPs/bp), which are
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likely to be evolving neutrally since their inactivation. Only for the
virulence-associated and transport/binding categories did the
SNP density difference reach statistical significance, however (P
0.02 and P  0.03, respectively). The high SNP density in the
transport/binding category was surprising, as this categorymostly
codes for housekeeping functions, including transport of mole-
cules such as amino acids, small ions, and carbohydrates. The high
SNPdensitymay reflect changes in the physiology ofB. pertussis or
the surface exposure of membrane and periplasmic components
of these systems.
To investigate this further, we tested whether the subcellular
location of proteins would result in significantly different degrees
of SNP density, as surface-exposed proteins are expected to be
subject to a higher degree of immune selection than intracellular
proteins. In line with this, we found that if categories were based
on subcellular location prediction, genes coding for proteins ex-
FIG 3 SNP densities per functional category (A), subcellular localization (B), and Bvg regulation (C). Red bars indicate the chromosomal average. Green bars
refer to categories with an SNP density significantly higher than the chromosomal average (P 0.05).
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posed to the host environment (extracellular and outer mem-
brane proteins) had the highest SNPdensity (0.0015 SNPs/bp;P
0.05), whereas genes coding for cytoplasmic proteins showed the
lowest SNP density (0.0012 SNPs/bp; P  1.0) (Fig. 3B; see Ta-
ble S5 in the supplemental material). In addition to the exposed
category, only the category “unknown,”which comprises proteins
for which we could not predict a location, showed an SNP density
which was significantly higher than the genomic average (0.0015
SNPs/bp; P  0.007). For example, Ptx subunits 2 to 5 are in-
cluded in the unknown category, although it is known that they
are secreted (51). Possibly this category compromises more genes
that encode surface-exposed proteins but for which the location
could not be predicted.
We also assessed the SNP density in gene categories based on
Bvg regulation (26, 27). For this, three categories were defined:
genes activated, repressed, or unaffected by Bvg (Fig. 3C; see Ta-
ble S5 in the supplemental material). The SNP density in these
three categories decreased in the order Bvg activated, Bvg re-
pressed, and not regulated by Bvg (SNP densities, 0.0015, 0.0014,
and 0.0013 SNPs/bp, respectively; P  0.013, P  0.40, and P 
1.0, respectively). The relatively high SNPdensity in Bvg-activated
genes was not unexpected, as genes encoding virulence-associated
proteins and extracellular proteins are included in this category.
Focusing on gene categories increased the power of the statis-
tical analyses but only gave a general picture and did not reveal
individual loci that might be under selection. Therefore, we also
identified particular loci whichwere highly polymorphic. For this,
we calculated whether there was an overrepresentation of SNPs in
a locus given its length (Table 2; see Table S5 in the supplemental
material). Two genes showed a significantly higher SNP density
than the chromosomal average of 0.0013 SNPs/bp in genes. One
gene encodes Ptx subunit A (ptxA) (0.011 SNPs/bp; P 0.0033).
The other gene, cysB (0.011 SNPs/bp; P  0.0029), encodes a
LysR-like transcriptional regulator that acts as an activator of the
cys genes and plays a role in sulfur metabolism (52, 53).
We also investigated SNP densities in intergenic regions, as
these may be involved in transcription of downstream genes. We
found four putative promoter regions with a significantly higher
SNP density than the chromosomal average of 0.0026 SNPs/bp in
intergenic regions (Table 2; see Table S5 in the supplemental ma-
terial). Two promoter regions were located upstream from
virulence-associated genes. One was upstream from the ptx
operon (0.071 SNPs/bp; P 4.7 1018), and one was between
the filamentous hemagglutinin gene (fhaB) and the bvg operon
(0.026 SNPs/bp; P 3.4 105). The extensive polymorphism in
the Ptx promoter has been described previously (14, 16). Eleven
SNPswere located in the intergenic region between the bvg operon
and fhaB, which has been studied extensively (54–58). Seven and
four SNPs were located in regions assumed to affect the transcrip-
tion of fhaB and bvgA, respectively (Text S2). While the SNPs in
the fhaB promoter may affect the expression of both fha and fim
genes, which are part of a single operon (59), the SNPs in the bvgA
promoter regionmay have a significant effect on the expression of
many virulence factors. A high SNP density was also observed in
the region upstream from a putative methylase possibly involved
in ubiquinone/menaquinone biosynthesis (0.036 SNPs/bp; P 
0.020) and in the promoter region of two hypothetical proteins
(0.020 SNPs/bp; P 0.018).
In conclusion, we identified significantly higher SNP densities
in virulence-associated genes, genes encoding surface-exposed
proteins, and genes activated by Bvg.High SNPdensities were also
observed in the promoter regions for ptx and bvg/fha. The finding
of a high SNP density in cysB was interesting, as a number of
associations have been observed between sulfur metabolism and
virulence (60). Indeed, in B. pertussis, the expression of virulence-
associated genes is affected by the sulfate concentration (28). The
identification of putative adaptive loci allows focused studies that
may reveal novel strategies for pathogen adaptation.
Homoplasic SNPs. In a second approach to find loci possibly
involved in adaptation, we identified homoplasic SNPs, that is,
SNPs which arose independently on different branches of the tree.
In our data set, 15 SNPs were homoplasic (Table 3). Thirty-
three percent of the homoplasic SNPs were located in Bvg-
activated genes, while this category only comprises 6% of the ge-
nome. The 5 SNPs found in Bvg-activated genes were located in
genes for the serotype 2 and 3 fimbrial subunits (fim2 and fim3), a
type III secretion protein (bscI), a Ptx transport protein (ptlB), and
a periplasmic solute-binding protein (smoM) involved in trans-
port of mannitol. Of the remaining 10 homoplasic SNPs, 6 and 4
were located in genes and intergenic regions, respectively. Re-
markably, one homoplasic SNP found in cysM was observed in
five branches. The cysM gene codes for cysteine synthase, which is
involved in cysteine biosynthesis and sulfate assimilation. All
other homoplasic SNPs occurred in two branches.
Convergent evolution is extremely rare in monomorphic bac-
teria like B. pertussis. In other monomorphic bacteria, homoplasy
TABLE 2 Genes and promoters with SNP densities significantly higher than the chromosomal average
Locus tag(s) Gene(s) Density (SNPs/bp) P value Product Categorya Localization(s)b Bvgc
3783BP ptxA 0.01111 3.3E-03 Pertussis toxin subunit A
precursor
Vir E 
2416BP cysB 0.01053 2.9E-03 LysR family transcriptional
regulator
Reg C
BP3783P ptxP 0.07143 4.7E-18 Pertussis toxin promoter Vir E 
BP2936P 0.03623 2.0E-02 Putative methylase promoter Exp CM 
BP1878P,
BP1879P
bvgP,
fhaBP
0.02582 3.4E-05 Virulence factor transcription
regulator promoter,
filamentous hemagglutinin
Vir C, OM ,
BP3723P,
BP3724P
0.02047 1.8E-02 Hypothetical protein promoter Hyp U, C
a Functional category: Vir, virulence-associated genes; Reg, regulation; Exp, exported proteins; Hyp, hypothetical proteins.
b Subcellular localization: E, extracellular; C, cytoplasmic; CM, cytoplasmic membrane; OM, outer membrane; U, unknown.
c Regulation by Bvg:, activated; blank cells, not activated or repressed.
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is usually only found in a few genes involved in antibiotic resis-
tance (61). This suggests that the homoplasic SNPs we have iden-
tified may play an important role in the adaptation of B. pertussis.
Gene loss. Several studies have shown that some B. pertussis
isolates contain DNA that is not in Tohama but is present in Bor-
detella bronchiseptica and Bordetella parapertussis (62–66). In this
work, we performed a de novo assembly of all of the genomes and
compared each assembly back against the reference Tohama I in
order to identify any genomic DNA that may have been acquired
since the origin ofB. pertussis. This analysis showed no evidence of
gene gain at any point in the phylogeny. All regions identified in
the sample data set that were not in Tohama are present in other
Bordetella pertussis genomes, such as 18323, consistent with gene
loss in Tohama. Placing these regions onto the tree showed that
progressive gene loss withinmultiple lineages can be observed (see
Fig. S3 in the supplemental material).
Summary. With the determination of the global population
structure of B. pertussis using whole-genome sequencing, we ad-
dressed key questions concerning the origin of pertussis, such as
the forces that have driven the shifts inB. pertussispopulations and
the role of these shifts in the resurgence of pertussis. Despite a
structure suggesting two relatively recent introductions of B. per-
tussis from an unknown reservoir, phylogenetic analysis did not
reveal the ancient geographic origin of B. pertussis, possibly be-
cause rapid worldwide spread and selective sweeps have elimi-
nated geographic signatures. Indeed, our results showed that the
mutation that resulted in the ptxP3 allele, which is associated with
an increase in pertussis notifications in at least two countries (14,
20), occurred once and strains carrying this new allele spread
worldwide in 25 to 30 years.
We confirmed and extended the observation that the world-
wide B. pertussis population has changed significantly in the last
TABLE 3 Homoplasic SNPs
Positiona Locus tag(s) Gene Branchesb Bootstrapc Changed
Product
(distance to ATG in bp) Functional category Localizatione Bvgf
612075 BP0607 gpm 2 (1, 3) 99 Silent Phosphoglycerate
mutase 1
Energy metabolism Cytoplasmic
667028 BP0658 2 (1, 19) 55 Q30 Putative dehydrogenase Miscellaneous Cytoplasmic
925864 BP0888 2 (7, 1) 100 Silent GntR family
transcriptional regulator
Regulation Cytoplasmic
997017 BP0958 cysM 5 (1, 1, 4, 2,
1)
100 G247E Cysteine synthase B Amino acid
biosynthesis
Cytoplasmic
1109310 1064BP maeB 2 (6, 1) 100 Silent NADP-dependent malic
enzyme
Central/intermediary
metabolism
Cytoplasmic
1109312 1064BP maeB 2 (6, 1) 100 Q28P NADP-dependent malic
enzyme
Central/intermediary
metabolism
Cytoplasmic
1175956 1119BP fim2 2 (7, 9) 100 R177K Serotype 2 fimbrial
subunit precursor
Virulence-
associated genes
Extracellular 
1565529 1487BP smoM 2 (1, 4) 100 R176K Putative periplasmic
solute-binding protein
Transport/binding
proteins
Unknown 
1647989 1568BP fim3 2 (1, 1) 98 T130A Serotype 3 fimbrial
subunit precursor
Virulence-
associated genes
Extracellular 
2018882 BP1914P 2 (1, 2) 100 Intergenic Transposase for IS1663
(321)
Phage or transposon
related
Unknown
BP1915P 2 (1, 2) 100 Intergenic Conserved hypothetical
protein (23)
Conserved
hypothetical
Unknown
2213448 BP2090P 2 (8, 1) 100 Intergenic ABC transporter
substrate-binding protein
(306)
Transport/binding
proteins
Periplasmic 
BP2091P 2 (8, 1) 100 Intergenic Dioxygenase hydroxylase
component (53)
Small molecule
degradation
Cytoplasmic 
2374322 2249BP bscI 2 (1, 97) 60 Y114C Type III secretion protein Virulence-
associated genes
Unknown 
3041105 BP2862P 2 (6, 1) 100 Intergenic Conserved hypothetical
protein (174)
Unknown Unknown
BP2863P 2 (6, 1) 100 Intergenic Conserved hypothetical
protein (148)
Unknown Cytoplasmic
3251279 BP3052P 2 (6, 2) 100 Intergenic Putative gamma-
glutamyl transpeptidase
(242)
Miscellaneous Periplasmic
3992064 3789BP ptlB 2 (1, 1) 69 Silent Pertussis toxin transport
protein
Virulence-
associated genes
CM 
a Position in reference genome B. pertussis Tohama I.
b Number of branches in which the homoplasic SNP occurred (number of strains/branch).
c Number of trees in which SNP is homoplasic (100 trees tested).
d Change in amino acid.
e Subcellular localization: CM, cytoplasmic membrane.
f Regulation by Bvg: activated; repressed; blank cells, not activated or repressed.
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60 years, consistent with other studies using temporally and geo-
graphically less diverse collections (15, 17–19, 21, 32, 34, 37–40).
We used several approaches to identify gene categories under se-
lection, including SNP density and homoplasy. These approaches
consistently suggested that Bvg-activated genes and genes coding
for surface-exposed proteins were important for adaptation. At
the individual gene level, four of the five genes for the components
of current ACVs were found to be particularly variable, underlin-
ing their role in inducing protective immunity and consistent with
vaccine-driven immune selection.
We identified other, less obvious genes which contained po-
tentially adaptive mutations, such as two genes involved in cys-
teine and sulfate metabolism (cysB and cysM). Sulfate can be used
to regulate virulence-associated genes in vitro (67), and our results
suggest that sulfate may also be an important cue during natural
infection. This result suggests that host-pathogen signaling and/or
the physiology of B. pertussis has changed over time.
Temporal analyses showed that most mutations in genes en-
coding acellular vaccine components arose in the period in which
theWCVwas used. It should be noted, however, that the period in
which theWCVwas used (30 to 40 years) is much longer than the
ACV period (7 to 15 years). These results are consistent with a
significant effect of vaccination on the B. pertussis population, as
suggested by previous studies (5, 20, 32, 39, 68). It seems plausible
that the changes in the B. pertussis populations have reduced vac-
cine efficacy.
Pathogen adaptations may reveal weak spots in the bacterial
defense, and hence, the loci under selective pressure may point to
ways to improve pertussis vaccines. Furthermore, many of the
putative adaptive loci we identified have a physiological role, and
future studies of these loci may reveal less obvious ways in which
the pathogen and host interact.
MATERIALS AND METHODS
Strains and sequencing.The clinical isolates used in this study are listed in
Table S1 in the supplemental material. DNA was isolated by the partici-
pants and sequenced using Illumina technology (69). Nineteen isolates
were sequenced using the Genome Analyzer II and resulting in single
reads of 37 bp (sequencing method 1). Thirty-eight isolates were se-
quenced using the Genome Analyzer II and resulting in paired-end reads
of 50 bp (sequencing method 2). The remaining isolates were sequenced
using 12 multiplexed tags on the Genome Analyzer II, producing paired-
end reads of 54 bp (sequencing method 3). The accession numbers of the
raw sequence data are listed in Table S1.
SNP detection. Reads for all sequenced samples were mapped against
the complete Tohama I reference genome sequence (accession number
BX470248) using SMALT (http://www.sanger.ac.uk/resources/software
/smalt/). Reads mapping with identical matches to two regions of the
reference genome were left unmapped. The alignment of reads around
insertions and deletions (indels) was improved using a combination of
pindel (70) to identify short indels and dindel (71) to realign the reads.
SNPs were identified using samtools mpileup (http://samtools
.sourceforge.net) and filtered as described previously (72)
Information about promoters, genes, and proteins was retrieved from
the sequenced genome of B. pertussis Tohama I. The annotation was up-
dated using BLAST (73), and domain information was recovered from
SMART (74) and Conserved Domain Database (75).
Homoplasic SNPs were identified by reconstructing base changes for
each variable site onto the phylogenetic tree under the parsimony crite-
rion. Any site for which the observed number of base changes for the
maximum parsimony reconstruction on the tree was greater than the
minimum possible number of changes for that site is homoplasic.
Phylogeny. The phylogenetic relationships of the entire data set were
inferred under a maximum likelihood framework using PHYML (76)
with an HKY85 model of evolution. The global phylogeny was rooted
using B. bronchiseptica MO149 (sequence type 15 [ST15]), which was
previously shown to be most closely related to B. pertussis (77, 78).
Mutation rates and ancestral node dates for lineage IIb were estimated
using Bayesian analysis in the BEAST version 1.6.2 package (79). Analyses
using the variable sites within lineage IIb isolates with isolation dates
available were run under a general time reversible (GTR) model of evolu-
tion, with all combinations of constant, expansion, logistic and skyline
population size models, and strict, relaxed exponential, and relaxed log-
normal clock models. For each combination, three independent Markov
chains were run for 100 million generations each, with parameter values
sampled every 1,000 generations. Chains were manually checked for rea-
sonable ESS values and for convergence between the three replicate chains
using Tracer. Tracer was also used to identify a suitable burn-in period to
remove from the beginning of each chain, as well as to assess the model
with the best fit to the data using Bayes factors. A skyline population
model with a relaxed exponential clock model was identified as the most
appropriate, so this combination of models was used for all further anal-
yses. It was found that, in each case, a burn-in of 10 million generations
was clearly past the pointwhere chains appeared to have converged, so this
was chosen as the burn-in for all chains. The burn-in was removed and
chains combined and down-sampled to every 10,000 generations using
LogCombiner. A Bayesian skyline plot was calculated in Tracer using the
default parameters, and a maximum clade credibility tree computed with
TreeAnnotator.
SNPdensities.The functional categories usedwere definedbyParkhill
et al. (30), with modifications, i.e., pseudogenes and genes known or as-
sumed to be associated with virulence were placed in separate categories.
Subcellular localization was predicted by PSORTb version 3.0 (80). Bvg
categories were defined based on the results of Streefland et al. (27) and
Cummings et al. (26). For the length of a specific category or locus repeat,
regions were excluded because SNPs in these regions are not reliable. To
determine the number of bases in a specific category, the lengths of the
included loci were added, excluding repeat regions. To determinewhether
the SNP density of a particular group or locus was significantly higher
than the chromosomal average, Fisher’s exact test was used. P values were
corrected according to the method of Benjamini and Hochberg (81).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org
/lookup/suppl/doi:10.1128/mBio.01074-14/-/DCSupplemental.
Table S1, XLSX file, 0.1 MB.
Table S2, XLSX file, 0.1 MB.
Table S3, XLSX file, 0.1 MB.
Table S4, XLSX file, 0.2 MB.
Table S5, XLSX file, 0.5 MB.
Figure S1, PDF file, 0.4 MB.
Figure S2, PDF file, 0.2 MB.
Figure S3, PDF file, 0.5 MB.
Text S1, DOCX file, 0.1 MB.
Text S2, PDF file, 0.1 MB.
ACKNOWLEDGMENTS
This effort was initiated during theBordetellaWorkshop in Cambridge on
22 to 24 July 2008. Therefore, we are very grateful to the attendees and
especially to Olivier Restif, who organized this meeting. We thank Gwen-
dolyn L. Gilbert (Westmead Hospital, Australia) and Margaret Ip (the
Chinese University of Hong Kong) for supplying strains.
This work was supported by the Wellcome Trust (grant number
098051), the RIVM (SOR project S/230446/01/BV), and the National
Health and Medical Research Council of Australia.
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Bart et al.
10 ® mbio.asm.org March/April 2014 Volume 5 Issue 2 e01074-14
REFERENCES
1. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha
P, Campbell H, Walker CF, Cibulskis R, Eisele T, Liu L, Mathers C,
Child Health Epidemiology Reference Group of WHO and UNICEF.
2010. Global, regional, and national causes of child mortality in 2008: a
systematic analysis. Lancet 375:1969–1987. http://dx.doi.org/10.1016/
S0140-6736(10)60549-1.
2. Still GF. 1965. The history of paediatrics. Oxford University Press, Lon-
don, United Kingdom.
3. Lapin JH. 1943. Whooping cough. Charles C. Thomas Publisher Ltd.,
Springfield, IL.
4. Magner LN. 1993. Diseases of the premodern period in Korea, p 392–400.
In Kiple KF (ed), The Cambridge world history of human disease. Cam-
bridge University Press, Cambridge, United Kingdom.
5. Mooi FR. 2010. Bordetella pertussis and vaccination: the persistence of a
geneticallymonomorphic pathogen. Infect. Genet. Evol. 10:36–49. http://
dx.doi.org/10.1016/j.meegid.2009.10.007.
6. Spokes PJ, Quinn HE, McAnulty JM. 2010. Review of the 2008-2009
pertussis epidemic in NSW: notifications and hospitalisations. N. S. W.
Public Health Bull. 21:167–173. http://dx.doi.org/10.1071/NB10031.
7. Health Protection Agency. 25 October 2012. Health protection report.
Vol 6No 43.Health ProtectionAgency, London England. http://www.hpa
.org.uk/hpr/archives/2012/hpr4312.pdf.
8. Conyn van Spaendock M, Van der Maas N, Mooi F. 2013. Control of
whooping cough in the Netherlands: optimisation of the vaccination pol-
icy. RIVM letter report 215121002. National Institute for Public Health
and the Environment, Bilthoven, The Netherlands. http://www.rivm.nl
/bibliotheek/rapporten/215121002.pdf.
9. Winter K, Harriman K, Zipprich J, Schechter R, Talarico J, Watt J,
Chavez G. 2012. California pertussis epidemic, 2010. J. Pediatr. 161:
1091–1096. http://dx.doi.org/10.1016/j.jpeds.2012.05.041.
10. DeBolt C, Tasslimi A, Bardi J, Leader B, Hiatt B, Quin X, Patel M,
Martin S, Tondella ML, Cassiday P, Faulkner A, Messonnier NE, Clark
TA, Meyer S. 2012. Pertussis epidemic—Washington, 2012. MMWR
Morb. Mortal. Wkly. Rep. 61:517–522.
11. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. 2012.
Waning protection after fifth dose of acellular pertussis vaccine in chil-
dren. N. Engl. J. Med. 367:1012–1019. http://dx.doi.org/10.1056/
NEJMoa1200850.
12. Sheridan SL, Ware RS, Grimwood K, Lambert SB. 2012. Number and
order of whole cell pertussis vaccines in infancy and disease protection.
JAMA 308:454–456. http://dx.doi.org/10.1001/jama.2012.6364.
13. Misegades LK, Winter K, Harriman K, Talarico J, Messonnier NE,
Clark TA, Martin SW. 2012. Association of childhood pertussis with
receipt of 5 doses of pertussis vaccine by time since last vaccine dose,
California, 2010. JAMA 308:2126–2132. http://dx.doi.org/10.1001/
jama.2012.14939.
14. Mooi FR, van Loo IH, van Gent M, He Q, Bart MJ, Heuvelman KJ, de
Greeff SC, Diavatopoulos D, Teunis P, Nagelkerke N, Mertsola J. 2009.
Bordetella pertussis strainswith increased toxin production associatedwith
pertussis resurgence. Emerg. Infect. Dis. 15:1206–1213. http://dx.doi.org/
10.3201/eid1508.081511.
15. van Gent M, Bart MJ, van der Heide HG, Heuvelman KJ, Mooi FR.
2012. Small mutations in Bordetella pertussis are associated with selective
sweeps . PLoS One 7:e46407 . ht tp : / /dx .doi .org/10 .1371/
journal.pone.0046407.
16. Advani A, Gustafsson L, Ahrén C, Mooi FR, Hallander HO. 2011.
Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions
of Sweden with different vaccination programs. Vaccine 29:3438–3442.
http://dx.doi.org/10.1016/j.vaccine.2011.02.070.
17. Hegerle N, Paris AS, Brun D, Dore G, Njamkepo E, Guillot S, Guiso N.
2012. Evolution of French Bordetella pertussis and Bordetella parapertussis
isolates: increase of bordetellae not expressing pertactin. Clin. Microbiol.
In fec t . 1 8 :E340 –E346 . ht tp : / /dx .do i .org /10 .1111/ j .1469-
0691.2012.03925.x.
18. Kallonen T, Mertsola J, Mooi FR, He Q. 2012. Rapid detection of the
recently emerged Bordetella pertussis strains with the ptxP3 pertussis toxin
promoter allele by real-time PCR. Clin. Microbiol. Infect. 18:E377–E379.
http://dx.doi.org/10.1111/j.1469-0691.2012.04000.x.
19. Lam C, Octavia S, Bahrame Z, Sintchenko V, Gilbert GL, Lan R. 2012.
Selection and emergence of pertussis toxin promoter ptxP3 allele in the
evolution of Bordetella pertussis. Infect. Genet. Evol. 12:492–495. http://
dx.doi.org/10.1016/j.meegid.2012.01.001.
20. Octavia S, Sintchenko V, Gilbert GL, Lawrence A, Keil AD, Hogg G,
Lan R. 2012. Newly emerging clones of Bordetella pertussis carrying prn2
and ptxP3 alleles implicated in Australian pertussis epidemic in 2008-
2010. J. Infect. Dis. 205:1220–1224. http://dx.doi.org/10.1093/infdis/
jis178.
21. Petersen RF, Dalby T, Dragsted DM, Mooi F, Lambertsen L. 2012.
Temporal trends in Bordetella pertussis populations, Denmark, 1949-
2010. Emerg. Infect. Dis. 18:767–774. http://dx.doi.org/10.3201/
eid1805.110812.
22. Schmidtke AJ, Boney KO, Martin SW, Skoff TH, Tondella ML, Tatti
KM. 2012. Population diversity amongBordetella pertussis isolates, United
States, 1935-2009. Emerg. Infect. Dis. 18:1248–1255. http://dx.doi.org/
10.3201/eid1808.120082.
23. Barkoff AM, Mertsola J, Guillot S, Guiso N, Berbers G, He Q. 2012.
Appearance of Bordetella pertussis strains not expressing the vaccine anti-
gen pertactin in Finland. Clin. Vaccine Immunol. 19:1703–1704. http://
dx.doi.org/10.1128/CVI.00367-12.
24. Otsuka N, Han HJ, Toyoizumi-Ajisaka H, Nakamura Y, Arakawa Y,
Shibayama K, Kamachi K. 2012. Prevalence and genetic characterization
of pertactin-deficient Bordetella pertussis in Japan. PLoS One 7:e31985.
http://dx.doi.org/10.1371/journal.pone.0031985.
25. Queenan AM, Cassiday PK, Evangelista A. 2013. Pertactin-negative
variants of Bordetella pertussis in the United States. N. Engl. J. Med. 368:-
583–584. http://dx.doi.org/10.1056/NEJMc1209369.
26. Cummings CA, Bootsma HJ, Relman DA, Miller JF. 2006. Species- and
strain-specific control of a complex, flexible regulon by Bordetella BvgAS.
J. Bacteriol. 188:1775–1785. http://dx.doi.org/10.1128/JB.188.5.1775-
1785.2006.
27. Streefland M, van de Waterbeemd B, Happé H, van der Pol LA,
Beuvery EC, Tramper J, Martens DE. 2007. PAT for vaccines: the first
stage of PAT implementation for development of a well-defined whole-
cell vaccine against whooping cough disease. Vaccine 25:2994–3000.
http://dx.doi.org/10.1016/j.vaccine.2007.01.015.
28. Stibitz S. 2007. The bvg regulon, p 47–67. In Locht C (ed), Bordetella
molecular microbiology. Horizon Bioscience, Norfolk, United Kingdom.
29. van Gent M, Bart MJ, van der Heide HG, Heuvelman KJ, Kallonen T,
He Q, Mertsola J, Advani A, Hallander HO, Janssens K, Hermans PW,
Mooi FR. 2011. SNP-based typing: a useful tool to study Bordetella per-
tussis populations. PLoS One 6:e20340. http://dx.doi.org/10.1371/
journal.pone.0020340.
30. Parkhill J, Sebaihia M, Preston A, Murphy LD, Thomson N, Harris DE,
Holden MT, Churcher CM, Bentley SD, Mungall KL, Cerdeño-Tárraga
AM, Temple L, James K, Harris B, Quail MA, Achtman M, Atkin R,
Baker S, Basham D, Bason N, Cherevach I, Chillingworth T, Collins M,
Cronin A, Davis P, Doggett J, Feltwell T, Goble A, Hamlin N, Hauser
H, Holroyd S, Jagels K, Leather S, Moule S, Norberczak H, O’Neil S,
Ormond D, Price C, Rabbinowitsch E, Rutter S, Sanders M, Saunders
D, Seeger K, Sharp S, Simmonds M, Skelton J, Squares R, Squares S,
Stevens K, Unwin L, Whitehead S, Barrell BG, Maskell DJ. 2003.
Comparative analysis of the genome sequences ofBordetella pertussis,Bor-
detella parapertussis and Bordetella bronchiseptica. Nat. Genet. 35:32–40.
http://dx.doi.org/10.1038/ng1227.
31. Moran NA, Plague GR. 2004. Genomic changes following host restriction
in bacteria. Curr. Opin. Genet. Dev. 14:627–633. http://dx.doi.org/
10.1016/j.gde.2004.09.003.
32. Litt DJ, Neal SE, Fry NK. 2009. Changes in genetic diversity of the
Bordetella pertussis population in the United Kingdom between 1920 and
2006 reflect vaccination coverage and emergence of a single dominant
clonal type. J. Clin. Microbiol. 47:680–688. http://dx.doi.org/10.1128/
JCM.01838-08.
33. Van Loo IH, Mooi FR. 2002. Changes in the Dutch Bordetella pertussis
population in the first 20 years after the introduction of whole-cell vac-
cines. Microbiology 148:2011–2018.
34. Weber C, Boursaux-Eude C, Coralie G, Caro V, Guiso N. 2001. Poly-
morphism of Bordetella pertussis isolates circulating for the last 10 years in
France, where a single effective whole-cell vaccine has been used for more
than 30 years. J. Clin. Microbiol. 39:4396–4403. http://dx.doi.org/
10.1128/JCM.39.12.4396-4403.2001.
35. Berbers GA, de Greeff SC, Mooi FR. 2009. Improving pertussis vaccina-
tion. Hum. Vaccine 5:497–503.
36. Williamson P, Matthews R. 1996. Epitope mapping the Fim2 and Fim3
Global Evolution of Bordetella pertussis
March/April 2014 Volume 5 Issue 2 e01074-14 ® mbio.asm.org 11
proteins of Bordetella pertussis with sera from patients infected with or
vaccinated against whooping cough. FEMS Immunol. Med. Microbiol.
13:169–178. http://dx.doi.org/10.1111/j.1574-695X.1996.tb00231.x.
37. Packard ER, Parton R, Coote JG, Fry NK. 2004. Sequence variation and
conservation in virulence-related genes of Bordetella pertussis isolates
from the UK. J. Med. Microbiol. 53:355–365. http://dx.doi.org/10.1099/
jmm.0.05515-0.
38. Octavia S, Maharjan RP, Sintchenko V, Stevenson G, Reeves PR,
Gilbert GL, Lan R. 2011. Insight into evolution of Bordetella pertussis
from comparative genomic analysis: evidence of vaccine-driven selection.
Mol. Biol. Evol. 28:707–715. http://dx.doi.org/10.1093/molbev/msq245.
39. Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra
W, Willems RJ. 1998. Polymorphism in the Bordetella pertussis virulence
factors, p 69/pertactin and pertussis toxin in The Netherlands: temporal
trends and evidence for vaccine-driven evolution. Infect. Immun. 66:
670–675.
40. Bottero D, Gaillard ME, Fingermann M, Weltman G, Fernández J, Sisti
F, Graieb A, Roberts R, Rico O, Ríos G, Regueira M, Binsztein N,
Hozbor D. 2007. Pulsed-field gel electrophoresis, pertactin, pertussis
toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and
clinical Bordetella pertussis strains. Clin. Vaccine Immunol. 14:
1490–1498. http://dx.doi.org/10.1128/CVI.00177-07.
41. King AJ, Berbers G, van Oirschot HF, Hoogerhout P, Knipping K, Mooi
FR. 2001. Role of the polymorphic region 1 of the Bordetella pertussis
protein pertactin in immunity. Microbiology 147:2885–2895.
42. Watanabe M, Nagai M. 2002. Effect of acellular pertussis vaccine against
various strains of Bordetella pertussis in a murine model of respiratory
infection. J. Health Sci. 48:560. http://dx.doi.org/10.1248/jhs.48.560.
43. Gzyl A, Augustynowicz E, Gniadek G, Rabczenko D, Dulny G, Slusarc-
zyk J. 2004. Sequence variation in pertussis S1 subunit toxin and pertussis
genes in Bordetella pertussis strains used for the whole-cell pertussis vac-
cine produced in Poland since 1960: efficiency of the DTwP vaccine-
induced immunity against currently circulating B. pertussis isolates. Vac-
cine 22:2122–2128. http://dx.doi.org/10.1016/j.vaccine.2003.12.006.
44. Komatsu E, Yamaguchi F, Abe A, Weiss AA, Watanabe M. 2010.
Synergic effect of genotype changes in pertussis toxin and pertactin on
adaptation to an acellular pertussis vaccine in the murine intranasal chal-
lenge model. Clin. Vaccine Immunol. 17:807–812. http://dx.doi.org/
10.1128/CVI.00449-09.
45. van Gent M, van Loo IH, Heuvelman KJ, de Neeling AJ, Teunis P, Mooi
FR. 2011. Studies on Prn variation in the mouse model and comparison
with epidemiological data. PLoSOne 6:e18014. http://dx.doi.org/10.1371/
journal.pone.0018014.
46. Denoël P, Godfroid F, Guiso N, Hallander H, Poolman J. 2005. Com-
parison of acellular pertussis vaccines-induced immunity against infec-
tion due to Bordetella pertussis variant isolates in a mouse model. Vaccine
23:5333–5341. http://dx.doi.org/10.1016/j.vaccine.2005.06.021.
47. Novichkov PS, Wolf YI, Dubchak I, Koonin EV. 2009. Trends in pro-
karyotic evolution revealed by comparison of closely related bacterial and
archaeal genomes. J. Bacteriol. 191:65–73. http://dx.doi.org/10.1128/
JB.01237-08.
48. Rocha EP, Smith JM, Hurst LD, Holden MT, Cooper JE, Smith NH,
Feil EJ. 2006. Comparisons of dN/dS are time dependent for closely re-
lated bacterial genomes. J. Theor. Biol. 239:226–235. http://dx.doi.org/
10.1016/j.jtbi.2005.08.037.
49. Yang Z, Bielawski JP. 2000. Statistical methods for detecting molecular
adaptation. Trends Ecol. Evol. 15:496–503. http://dx.doi.org/10.1016/
S0169-5347(00)01994-7.
50. Kudla G, Murray AW, Tollervey D, Plotkin JB. 2009. Coding-sequence
determinants of gene expression in Escherichia coli. Science 324:255–258.
http://dx.doi.org/10.1126/science.1170160.
51. Locht C, Coutte L, Mielcarek N. 2011. The ins and outs of pertussis toxin.
FEBS J. 278:4668 – 4682. http: / /dx.doi .org/10.1111/ j .1742-
4658.2011.08237.x.
52. Imperi F, Tiburzi F, Fimia GM, Visca P. 2010. Transcriptional control of
the pvdS iron starvation sigma factor gene by themaster regulator of sulfur
metabolism CysB in Pseudomonas aeruginosa. Environ. Microbiol. 12:
1630–1642. doi: 10.1111/j.1462-2920.2010.02210.x.
53. Kredich NM. 1992. The molecular basis for positive regulation of cys
promoters in Salmonella typhimurium and Escherichia coli. Mol. Micro-
b io l . 6 :2747–2753 . ht tp : / /dx .do i .org /10 .1111/ j .1365-
2958.1992.tb01453.x.
54. Boucher PE, Maris AE, Yang MS, Stibitz S. 2003. The response regulator
BvgA and RNApolymerase alpha subunit C-terminal domain bind simul-
taneously to different faces of the same segment of promoter DNA. Mol.
Cell 11:163–173. http://dx.doi.org/10.1016/S1097-2765(03)00007-8.
55. Boucher PE, Murakami K, Ishihama A, Stibitz S. 1997. Nature of DNA
binding and RNA polymerase interaction of the Bordetella pertussis BvgA
transcriptional activator at the fha promoter. J. Bacteriol. 179:1755–1763.
56. Boucher PE, Yang MS, Schmidt DM, Stibitz S. 2001. Genetic and
biochemical analyses of BvgA interaction with the secondary binding re-
gion of the fha promoter of Bordetella pertussis. J. Bacteriol. 183:536–544.
http://dx.doi.org/10.1128/JB.183.2.536-544.2001.
57. Boucher PE, Yang MS, Stibitz S. 2001. Mutational analysis of the high-
affinity BvgA binding site in the fha promoter of Bordetella pertussis. Mol.
Microbio l . 40:991–999 . ht tp : / /dx .doi .org/10 .1046/ j .1365-
2958.2001.02442.x.
58. Decker KB, Chen Q, Hsieh ML, Boucher P, Stibitz S, Hinton DM. 2011.
Different requirements for  region 4 in BvgA activation of the Bordetella
pertussis promoters P(fim3) and P(fhaB). J. Mol. Biol. 409:692–709.
http://dx.doi.org/10.1016/j.jmb.2011.04.017.
59. Mattoo S, Miller JF, Cotter PA. 2000. Role of Bordetella bronchiseptica
fimbriae in tracheal colonization and development of a humoral immune
response. Infect. Immun. 68:2024–2033. http://dx.doi.org/10.1128/
IAI.68.4.2024-2033.2000.
60. Łochowska A, Iwanicka-Nowicka R, Zielak A, Modelewska A, Thomas
MS, Hryniewicz MM. 2011. Regulation of sulfur assimilation pathways in
Burkholderia cenocepacia through control of genes by the SsuR transcrip-
tion factor. J. Bacteriol. 193:1843–1853. http://dx.doi.org/10.1128/
JB.00483-10.
61. Achtman M. 2012. Insights from genomic comparisons of genetically
monomorphic bacterial pathogens. Philos. Trans. R. Soc. Lond. B Biol.
Sci. 367:860–867. http://dx.doi.org/10.1098/rstb.2011.0303.
62. Brinig MM, Cummings CA, Sanden GN, Stefanelli P, Lawrence A,
Relman DA. 2006. Significant gene order and expression differences in
Bordetella pertussis despite limited gene content variation. J. Bacteriol.
188:2375–2382. http://dx.doi.org/10.1128/JB.188.7.2375-2382.2006.
63. Caro V, Bouchez V, Guiso N. 2008. Is the sequenced Bordetella pertussis
strain Tohama I representative of the species? J. Clin. Microbiol. 46:
2125–2128. http://dx.doi.org/10.1128/JCM.02484-07.
64. Bouchez V, Caro V, Levillain E, Guigon G, Guiso N. 2008. Genomic
content of Bordetella pertussis clinical isolates circulating in areas of inten-
sive children vaccination. PLoS One 3:e2437. http://dx.doi.org/10.1371/
journal.pone.0002437.
65. King AJ, van Gorkom T, van der Heide HG, Advani A, van der Lee S.
2010. Changes in the genomic content of circulating Bordetella pertussis
strains isolated from the Netherlands, Sweden, Japan and Australia: adap-
tive evolution or drift? BMC Genomics 11:64. http://dx.doi.org/10.1186/
1471-2164-11-64.
66. Bart MJ, van Gent M, van der Heide HG, Boekhorst J, Hermans P,
Parkhill J, Mooi FR. 2010. Comparative genomics of prevaccination and
modern Bordetella pertussis strains. BMC Genomics 11:627. http://
dx.doi.org/10.1186/1471-2164-11-627.
67. Bogdan JA, Nazario-Larrieu J, Sarwar J, Alexander P, Blake MS. 2001.
Bordetella pertussis autoregulates pertussis toxin production through the
metabolism of cysteine. Infect. Immun. 69:6823–6830. http://dx.doi.org/
10.1128/IAI.69.11.6823-6830.2001.
68. Njamkepo E, Cantinelli T, Guigon G, Guiso N. 2008. Genomic analysis
and comparison of Bordetella pertussis isolates circulating in low and high
vaccine coverage areas. Microbes Infect. 10:1582–1586. http://dx.doi.org/
10.1016/j.micinf.2008.09.012.
69. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J,
Brown CG, Hall KP, Evers DJ, Barnes CL, Bignell HR, Boutell JM,
Bryant J, Carter RJ, Keira Cheetham R, Cox AJ, Ellis DJ, Flatbush MR,
Gormley NA, Humphray SJ, Irving LJ, Karbelashvili MS, Kirk SM, Li
H, Liu X, Maisinger KS, Murray LJ, Obradovic B, Ost T, Parkinson ML,
Pratt MR, Rasolonjatovo IM, Reed MT, Rigatti R, Rodighiero C, Ross
MT, Sabot A, Sankar SV, Scally A, Schroth GP, Smith ME, Smith VP,
Spiridou A, Torrance PE, Tzonev SS, Vermaas EH, Walter K, Wu X,
Zhang L, Alam MD, Anastasi C, et al. 2008. Accurate whole human
genome sequencing using reversible terminator chemistry. Nature 456:
53–59. http://dx.doi.org/10.1038/nature07517.
70. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. 2009. Pindel: a pattern
growth approach to detect breakpoints of large deletions and medium
sized insertions from paired-end short reads. Bioinformatics 25:
2865–2871. http://dx.doi.org/10.1093/bioinformatics/btp394.
Bart et al.
12 ® mbio.asm.org March/April 2014 Volume 5 Issue 2 e01074-14
71. Albers CA, Lunter G, MacArthur DG, McVean G, Ouwehand WH,
Durbin R. 2011. Dindel: accurate indel calls from short-read data. Ge-
nome Res. 21:961–973. http://dx.doi.org/10.1101/gr.112326.110.
72. Harris SR, Feil EJ, Holden MT, Quail MA, Nickerson EK, Chantratita
N, Gardete S, Tavares A, Day N, Lindsay JA, Edgeworth JD, de Len-
castre H, Parkhill J, Peacock SJ, Bentley SD. 2010. Evolution of MRSA
during hospital transmission and intercontinental spread. Science 327:
469–474. http://dx.doi.org/10.1126/science.1182395.
73. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local
alignment search tool. J. Mol. Biol. 215:403–410. http://dx.doi.org/
10.1016/S0022-2836(05)80360-2.
74. Schultz J, Milpetz F, Bork P, Ponting CP. 1998. SMART, a simple
modular architecture research tool: identification of signaling domains.
Proc. Natl. Acad. Sci. U. S. A. 95:5857–5864.
75. Marchler-Bauer A, Zheng C, Chitsaz F, Derbyshire MK, Geer LY, Geer
RC, Gonzales NR, Gwadz M, Hurwitz DI, Lanczycki CJ, Lu F, Lu S,
Marchler GH, Song JS, Thanki N, Yamashita RA, Zhang D, Bryant SH.
2013. CDD: conserved domains and protein three-dimensional structure.
Nucleic Acids Res. 41:D348–D352. http://dx.doi.org/10.1093/nar/gks1243.
76. Guindon S, Gascuel O. 2003. A simple, fast, and accurate algorithm to
estimate large phylogenies by maximum likelihood. Syst. Biol. 52:
696–704. http://dx.doi.org/10.1080/10635150390235520.
77. Diavatopoulos DA, Cummings CA, Schouls LM, Brinig MM, Relman
DA, Mooi FR. 2005. Bordetella pertussis, the causative agent of whooping
cough, evolved from a distinct, human-associated lineage of B. bron-
chiseptica. PLoS Pathog. 1:e45. http://dx.doi .org/10.1371/
journal.ppat.0010045.
78. Park J, Zhang Y, Buboltz AM, Zhang X, Schuster SC, Ahuja U, Liu M,
Miller JF, Sebaihia M, Bentley SD, Parkhill J, Harvill ET. 2012. Com-
parative genomics of the classical Bordetella subspecies: the evolution and
exchange of virulence-associated diversity amongst closely related patho-
gens. BMC Genomics 13:545. http://dx.doi.org/10.1186/1471-2164-13-
545.
79. Drummond AJ, Suchard MA, Xie D, Rambaut A. 2012. Bayesian phy-
logenetics with BEAUti and the BEAST. Mol. Biol. Evol. 29:1969–1973.
http://dx.doi.org/10.1093/molbev/mss075.
80. Yu NY, Laird MR, Spencer C, Brinkman FS. 2011. PSORTdb—an
expanded, auto-updated, user-friendly protein subcellular localization
database for Bacteria and Archaea. Nucleic Acids Res. 39:D241–D244.
http://dx.doi.org/10.1093/nar/gkq1093.
81. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a
practical and powerful approach to multiple testing. J. R. Stat. Soc. B Stat.
Methodol. 57:289–300.
Global Evolution of Bordetella pertussis
March/April 2014 Volume 5 Issue 2 e01074-14 ® mbio.asm.org 13
